Literature DB >> 20438046

Long-term ophthalmological follow-up of children with Parinaud syndrome.

Nitza Goldenberg-Cohen1, Jordana Haber, Yonina Ron, Liora Kornreich, Helen Toledano, Moshe Snir, Ian J Cohen, Shalom Michowiz.   

Abstract

BACKGROUND AND
OBJECTIVE: To assess the long-term ophthalmological outcome of Parinaud syndrome. PATIENTS AND METHODS: The files of 6 children with tumor-related Parinaud syndrome diagnosed and observed from 2000 to 2007 were reviewed. All had papilledema indicating increased intracranial pressure.
RESULTS: Mean presentation-to-diagnosis delay was 3.6 weeks. Treatment consisted of surgical shunting and complete or partial resection with adjuvant chemotherapy (n = 4) and radiation (n = 3). Visual acuity remained stable or improved in 8 of 9 eyes with 20/30 visual acuity at diagnosis; improved bilaterally in 1 patient from 20/100 to 20/25; and deteriorated bilaterally in 1 patient from 20/30 and 20/200 to counting fingers and hand motions, respectively. The most improvement was achieved within 4 months. Findings at follow-up (mean: 4.2 years) included up gaze limitation (minimal in 2 patients), abnormal convergence, convergence retraction nystagmus, and light-near dissociation. One child had bilateral optic atrophy.
CONCLUSION: Children with tumor-related Parinaud syndrome tend to have subtle but measurable residual ophthalmological findings years after diagnosis and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20438046     DOI: 10.3928/15428877-20100426-02

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Children with dorsal midbrain syndrome as a result of pineal tumors.

Authors:  Mary Ellen Hoehn; Julie Calderwood; Thomas O'Donnell; Gregory T Armstrong; Amar Gajjar
Journal:  J AAPOS       Date:  2017-01-07       Impact factor: 1.220

2.  MRI findings in Parinaud's syndrome: a closer look at pineal masses.

Authors:  Amrita-Amanda D Vuppala; Nanki Hura; Sadaf Sahraian; Elham Beheshtian; Neil R Miller; David M Yousem
Journal:  Neuroradiology       Date:  2019-01-25       Impact factor: 2.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.